TCLF 2015



Ro-CHOP: Toxicity increases with efficacy

Jen Smith Read Article
Published: 02/10/15

Bertrand Coiffier, MD, PhD
Photo by Larry Young

Adding romidepsin to CHOP can enhance the regimen’s efficacy against peripheral T-cell lymphoma (PTCL), but the combination can also induce severe toxicity, results of a phase 1b/2 study have shown. In patients with previously untreated PTCL, romidepsin plus CHOP elicited an overall response rate of about 69%. But all patients experienced adverse events, a median of 49 per patient. In addition, rates of hematologic toxicities were high, and 3 patients experienced acute cardiac toxicity. [Read Article]

Mogamulizumab in PTCL: Europe vs Japan

Jen Smith Read Article
Published: 02/09/15

Pier Luigi Zinzani, MD, PhD
Photo by Larry Young

Two phase 2 studies testing mogamulizumab in peripheral T-cell lymphomas (PTCLs) suggest that higher response rates don’t necessarily translate to an improvement in progression-free survival (PFS). The anti-CCR4 antibody produced a higher overall response rate (ORR) in a Japanese study than in a European study—34% and 11%, respectively. However, median PFS times were similar—about 2 months in both studies. [Read Article]

MicroRNA may be therapeutic target for ALK- ALCL

Jen Smith Read Article
Published: 02/05/15

Philipp Staber, MD, PhD
Photo by Larry Young

MicroRNA-155 (miR-155) can act as an oncogenic driver in ALK- anaplastic large-cell lymphoma (ALCL) and may therefore be a therapeutic target for the disease, according to a presentation at the 7th Annual T-cell Lymphoma Forum. Analyzing patient samples and cell lines, researchers discovered that miR-155 is highly expressed in ALK− ALCL but is nearly absent in ALK+ ALCL. They also found evidence suggesting that miR-155 drives tumor growth in mouse models of ALK− ALCL. [Read Article]

Combo shows early promise for T-cell lymphomas

Jen Smith Read Article
Published: 02/04/15

Michelle Fanale, MD
Photo by Larry Young

Preclinical and early phase 1 results suggest the aurora A kinase inhibitor alisertib and the histone deacetylase (HDAC) inhibitor romidepsin have synergistic activity against T-cell lymphomas. In the preclinical study, the drugs showed synergy in cutaneous T-cell lymphoma (CTCL) cell lines and a benefit over monotherapy in vivo. In the phase 1 study, romidepsin and alisertib produced clinical benefits in patients with peripheral T-cell lymphoma (PTCL). [Read Article]

A better HDAC inhibitor for PTCL?

Jen Smith Read Article
Published: 02/03/15

Yuankai Shi, MD, PhD
Photo by Larry Young

The histone deacetylase (HDAC) inhibitor chidamide is effective and well-tolerated in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), results of the phase 2 CHIPEL trial suggest. The study showed that chidamide can elicit higher response rates than those previously observed with pralatrexate and romidepsin. Chidamide also prolonged survival and posed a lower risk of toxicity compared to pralatrexate and romidepsin. [Read Article]

Outcomes still dismal in PTCL, project shows

Jen Smith Read Article
Published: 02/02/15

Massimo Federico, MD
Photo by Larry Young

Outcomes remain dismal for the majority of patients with peripheral T-cell lymphoma (PTCL), according to a speaker at the 7th Annual T-cell Lymphoma Forum. Massimo Federico, MD, of the Università di Modena e Reggio Emilia in Italy, presented an analysis of the first 1000 patients enrolled in the prospective T-Cell Project. The data showed no improvements in survival for these patients compared to patients included in the retrospective International Peripheral T-Cell Lymphoma Project. [Read Article]

Distribution of PTCL subtypes varies by race/ethnicity

Jen Smith Read Article
Published: 02/02/15

Andrei Shustov, MD
Photo by Larry Young

The distribution of peripheral T-cell lymphoma (PTCL) subtypes in the US varies greatly according to race and ethnicity, new research suggests. The retrospective study showed that the overall incidence of PTCL and its subtypes is lower in American Indians and Alaskan Natives than in other ethnic groups. And the black population has a significantly higher incidence of PTCL—and the most common subtype, PTCL-not otherwise specified (NOS)—than other populations. [Read Article]


    {icon} {author} Read Article
    Published: {pubDate}